Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):175–182. doi: 10.1097/QAI.0000000000001655

Table 2.

Pharmacodynamics: % inhibition of HIV, Mean (Standard Deviation)

Vaginal use phase Rectal use phase
Pre-
dose
Post-
dose
% change, post-
versus pre-
dosing
Pre-
dose
Post-
dose
% change,
post- versus
pre-dosing
Cervical vaginal lavage fluid, 1:4 dilution 41 (14) 71 (29) 42% 39 (16) 42 (18) 7%
Rectal fluid (sponge), 1:37.5 dilution 51 (39) 59 (29) 14% 50 (38) 43 (50) −14%